- Home
- SEVN vs LRMR Comparison
SEVN vs LRMR Comparison
Compare SEVN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- LRMR
- Stock Information
- Founded
- SEVN 1986
- LRMR N/A
- Country
- SEVN United States
- LRMR United States
- Employees
- SEVN N/A
- LRMR N/A
- Industry
- SEVN Real Estate Investment Trusts
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- LRMR Health Care
- Exchange
- SEVN Nasdaq
- LRMR Nasdaq
- Market Cap
- SEVN 173.7M
- LRMR 191.4M
- IPO Year
- SEVN N/A
- LRMR N/A
- Fundamental
- Price
- SEVN $12.85
- LRMR $3.09
- Analyst Decision
- SEVN Strong Buy
- LRMR Strong Buy
- Analyst Count
- SEVN 3
- LRMR 7
- Target Price
- SEVN $14.75
- LRMR $17.86
- AVG Volume (30 Days)
- SEVN 48.7K
- LRMR 1.4M
- Earning Date
- SEVN 07-28-2025
- LRMR 08-06-2025
- Dividend Yield
- SEVN 10.89%
- LRMR N/A
- EPS Growth
- SEVN N/A
- LRMR N/A
- EPS
- SEVN 1.15
- LRMR N/A
- Revenue
- SEVN $30,074,000.00
- LRMR N/A
- Revenue This Year
- SEVN $7.45
- LRMR N/A
- Revenue Next Year
- SEVN $1.12
- LRMR N/A
- P/E Ratio
- SEVN $11.18
- LRMR N/A
- Revenue Growth
- SEVN N/A
- LRMR N/A
- 52 Week Low
- SEVN $10.18
- LRMR $1.61
- 52 Week High
- SEVN $14.66
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- SEVN 64.41
- LRMR 60.78
- Support Level
- SEVN $11.78
- LRMR $2.81
- Resistance Level
- SEVN $12.77
- LRMR $3.19
- Average True Range (ATR)
- SEVN 0.28
- LRMR 0.30
- MACD
- SEVN 0.08
- LRMR 0.01
- Stochastic Oscillator
- SEVN 78.26
- LRMR 82.43
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.